<DOC>
	<DOCNO>NCT00453362</DOCNO>
	<brief_summary>This single-arm , open-label , multicenter , international pilot study evaluate change occur 2-deoxy-2- [ 18F ] fluoro-D-glucose ( FDG ) - 3'-deoxy-3'- [ 18F ] fluorothymidine ( FLT ) -PET ( Positron Emission Tomography ) image result treatment erlotinib patient recurrent refractory non−small cell lung cancer ( NSCLC ) . The study enroll approximately 30 patient approximately 4 site Australia 2 site United States .</brief_summary>
	<brief_title>A Study Changes FDG- FLT-PET Imaging Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<criteria>Signed Informed Consent Form ( ) Histologically confirm NSCLC Recurrent progressive disease receive least one chemotherapy regimen advance metastatic NSCLC Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Age ≥ 18 year Recovery reversible acute effect prior anticancer therapy ( chemotherapy , radiotherapy , investigational treatment ) NCI Common Toxicity Criteria Adverse Events ( NCI CTCAE ) Grade ≤ 1 ( exclude alopecia ) Ability comply study followup procedure , include specify imaging study Ability take oral medication Availability archival diagnostic paraffinembedded tumor tissue willingness provide sufficient tissue test EGFR level tumor immunohistochemistry ( IHC ) fluorescence situ hybridization ( FISH ) Life expectancy ≥ 3 month Measurable disease compute tomography ( CT ) At least one detectable lesion FDGPET scan and/or FLTPET scan measurable CT Use acceptable mean contraception ( men woman childbearing potential ) documentation infertility Prior treatment investigational market agent purpose inhibit epidermal growth factor receptor ( EGFR ) ( include , limited , erlotinib gefitinib ) Chemotherapy , radiotherapy , investigational treatment within 14 day within 5 halflives active molecule chemotherapy investigational treatment , whichever longer , prior study entry patient yet recover Inability take oral medication , disease affect gastrointestinal absorption , prior surgical procedure affect gastrointestinal absorption Uncontrolled diabetes Any unstable systemic disease ( include active infection , unstable angina , congestive heart failure , myocardial infarction within 1 month prior study entry , hepatic , renal , metabolic disease ) Pregnancy lactation History another malignancy past 2 year , unless malignancy adequately treat , currently detectable , associated 5year survival &gt; 90 % Claustrophobia Any disease , condition , physical examination finding , clinical laboratory finding , opinion investigator , make patient inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Positron emission technology</keyword>
	<keyword>PET</keyword>
	<keyword>Computerized tomography</keyword>
	<keyword>CT</keyword>
</DOC>